Results 51 to 60 of about 12,926,306 (256)

A Novel IDO1/NE Dual Inhibitor, IMM‐H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression

Advanced Science, EarlyView.
IMM‐H018, a dual IDO1/NE inhibitor, demonstrates potent therapeutic efficacy in sepsis by simultaneously targeting excessive inflammation and immune dysfunction. It prevents both primary and secondary sepsis through anti‐inflammatory, immune‐restoring, and renoprotective mechanisms, reducing organ damage, improving immune homeostasis, preserving kidney
Yi Zhou, Xiaodi Zhao, Xiaochen Pan, Zhiling Ma, Huaqing Cui, Hui Wen, Peng Wang, Xiufeng Liao, Kejie Qin, Yuchen Wang, Li Sheng, Sen Zhang   +11 more
wiley   +1 more source

Association of CTLA-4 polymorphisms with hematologic malignancy susceptibility: a meta-analysis

Frontiers in Oncology
BackgroundRecent studies have reported an association between Cytotoxic T-lymphocyte antigen-4 (CTLA-4) polymorphisms and hematologic malignancy susceptibility, while the results remain inconsistent. Hence, we performed a meta-analysis to investigate the
Xuefen Yan, Nana Zhang, Gang Wang, Jiaheng Wang   +3 more
doaj   +1 more source

Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4

Frontiers in Oncology, 2020
Patients with triple-negative breast cancer (TNBC) have a poor prognosis, partly because of the absence of targeted therapies. Recognition of the key role of immune responses against cancer has allowed the advent of immunotherapy, focused on the ...
María G. C. Navarrete-Bernal, Mayte G. Cervantes-Badillo, Mayte G. Cervantes-Badillo, Jose Fabián Martínez-Herrera, César O. Lara-Torres, Raquel Gerson-Cwilich, Alejandro Zentella-Dehesa, Alejandro Zentella-Dehesa, Alejandro Zentella-Dehesa, María de Jesús Ibarra-Sánchez, María de Jesús Ibarra-Sánchez, José Esparza-López, José Esparza-López, Juan J. Montesinos, Víctor Adrián Cortés-Morales, Diego Osorio-Pérez, Diana A. Villegas-Osorno, Eduardo Reyes-Sánchez, Pablo Salazar-Sojo, Luis F. Tallabs-Utrilla, Sandra Romero-Córdoba, Sandra Romero-Córdoba, Leticia Rocha-Zavaleta, Leticia Rocha-Zavaleta   +23 more
doaj   +1 more source

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody [PDF]

, 2018
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells.
Nicholas S Wilson, Robert Stein, Taha Merghoub (217303), Andrea Schuster (3861352), Jedd D Wolchok, Mariana Manrique (5058668), Jennifer S Buell, Christopher Clarke (2849210), Jeremy D. Waight (195980), Elise E. Drouin (5058647), David Savitsky, Randi B. Gombos, David Schaer (5058644), Hao Tang, Christopher Dupont (815109), Benjamin Morin, Jennifer S. Buell, Mark A Findeis, Cornelia Mundt (5058659), Ekaterina Breous-Nystrom (5058638), Cornelia Mundt, Marc van Dijk (18075), Dhan Chand, Christopher Clarke, Dennis Underwood (5058656), Dhan Chand (5058662), Rebecca A Ward, Jedd D. Wolchok, Jennifer S. Buell (5058641), Ana Gonzalez (77722), Hao Tang (44155), Elise E. Drouin, Nicholas S. Wilson, Gerd Ritter (209869), Ana Gonzalez, Jeremy D Waight, Jedd D. Wolchok (217325), Andrea Schuster, Rebecca A. Ward, Benjamin Duckless (5058653), Christopher Dupont, Benjamin Duckless, Taha Merghoub, Jean-Marie Cuillerot (5058671), Randi B. Gombos (5058665), Benjamin Morin (241832), Dennis Underwood, David Savitsky (5058650), Jean-Marie Cuillerot, David Schaer, Jeremy D. Waight, Mark A. Findeis (2020771), Elise E Drouin, Ekaterina Breous-Nystrom, Robert Stein (1704328), Randi B Gombos, Rebecca A. Ward (5058674), Nicholas S. Wilson (5058677), Mariana Manrique, Marc van Dijk, Mark A. Findeis, Gerd Ritter   +61 more
core   +1 more source

Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection

Advanced Science, EarlyView.
Dual LILRB1/B2 blockade with mac20G10 reshapes myeloid activation during acute SIV infection by targeting LILRB1 and LILRB2 on myeloid cells. This treatment enhances CD80 expression on selected myeloid subsets and increases plasma IFN‐λ, IL‐8, and IL‐1RA.
Florian Meurisse, Sixtine Coindre, Anne Wijkhuisen, Romain Marlin, Laure Fournier Le Ray, Juliette Pons, Melyssa Yaugel‐Novoa, Véronique Avettand‐Fenoel, Laurent Abi‐Rached, Anne‐Sophie Gallouet, Francis Relouzat, Mael Gourves, Asier Saez‐Cirion, Hisashi Arase, Gerard Zurawski, Sandra Zurawski, Nathalie Dereuddre‐Bosquet, Roger Le Grand, Stéphanie Simon, Olivier Lambotte, Benoit Favier   +20 more
wiley   +1 more source

Anti-PD-1 and anti-CTLA-4 treatment of Hep_Frag tumors.

, 2019
A, Treatment schedule: anti-PD-1 (10 mg/kg, i.p.) and anti-CTLA-4 (5 mg/kg, i.p.) therapy started at day 25 after fragment implantation and was applied in 3 doses at days 0, 3 and 7.
Veronika Schandl (6941093), Carola H. Ries (144688), Carina Hage (6941084), Fabian Kiessling (535383), Christian Heichinger (6941102), Sabine Hoves (6941087), Mailin Ashoff (6941090), Natascha Rieder (6941099), Marco Berrera (82653), Stefan Hört (6941096), Thomas Pöschinger (6941105)   +10 more
core   +1 more source

Additional file 2 of Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors

, 2021
Additional file 2: Table S1. CoGAPS 21 pattern matrix with pattern weights for each cell. Table S2. FDR adjusted gene set statistics for all 21 CoGAPS patterns. Table S3.
Emily F. Davis-Marcisak (9547348), Elizabeth M. Jaffee (7610147), Elana J. Fertig (9520792), Ludmila Danilova (3427982), Louis M. Weiner (11257778), Michael D. Kessler (5108738), Allison A. Fitzgerald (11257775), Neeha Zaidi (6244229)   +7 more
core   +1 more source

ICOS‐ImmunoPET Monitors T Cell Activation After Combination Immune Checkpoint Blockade in a Mouse Model of Melanoma Brain Metastasis

Advanced Science, EarlyView.
ICOS‐immunoPET noninvasively visualizes activated T cells in melanoma brain metastases following combined anti‐PD‐1/anti‐CTLA‐4 therapy. Clinical translation of this imaging approach may improve patient stratification and treatment monitoring and serve as a quantitative imaging endpoint to support immunotherapy development and clinical trials in brain ...
Renesmee C. Kuo, Rohit Verma, Sydney C. Nagy, Mausam Kalita, Samuel Aubert, Josué Ballesteros‐Álvarez, Pedro Machado Almeida, Hannes Vogel, Israt S. Alam, Michael Lim, Michelle L. James   +10 more
wiley   +1 more source

Supplementary Figures 1 - 4 from Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

, 2013
PDF file - 206K, Supplemental Figure S1. Equivalent binding of anti-CTLA-4 isotypes to cell surface CTLA-4. Supplemental Figure S2. Serum concentrations of anti-CTLA-4 isotypes in C57BL/6 mice. Supplemental Figure S3.
Mark J. Selby (3110964), Timothy Chen (3575390), Mohan Srinivasan (15111947), John J. Engelhardt (3110952), Karla A. Henning (15111944), Michael Quigley (3110970), Alan J. Korman (14907909)   +6 more
core   +1 more source

Blood Cell‐Camouflaged Liquid Metal Nanoconjugates Orchestrate Treg Depletion and STING‐Amplified Photothermal Immunity for Metastatic Triple‐Negative Breast Cancer Therapy

Advanced Science, EarlyView.
Whole‐blood biomimetic engineering transforms liquid metal nanoparticles into a tripartite immunotherapeutic platform that orchestrates regulatory T‐cell depletion, photothermal‐induced immunogenic cell death, and activation of the stimulator of interferon genes pathway.
Nina Sang, Eijiro Miyako
wiley   +1 more source